NCT04290923CompletedNot Applicable
Determination of Blood Tumor Cells Using Magnetic Nanoparticles
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- University of Zurich
- Enrollment
- 71
- Locations
- 1
- Primary Endpoint
- Number of CTC / lymphocytes removed
Study Overview
Brief Summary
Magnetic nanoparticles coated with anti-EpCAM or anti-CD52 antibodies will be tested ex-vivo in patients blood .
Detailed Description
Magnetic nanoparticles, coated with epithelial cell adhesion molecule (EpCAM)-antibodies are designed to interact with epithelial tumor cells. Aim of this study is to see if circulating tumor cells (EpCAM as marker)can be removed out of the blood with the help of these particles. Patients suffering from prostate, colon, lung or pancreatic cancer will be asked to test their blood.
Similarly, magnetic nanoparticles will be coated with antibodies, directed against non-solid tumors in the blood such as lymphoma or leukemia (CD52 as marker).
Study Design
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Prospective
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Epithelial cell cancer, advanced stage Non-solid tumors (lymphoma, leukemia)
Exclusion Criteria
- •Inability to understand the language of the center (German)
Outcomes
Primary Outcomes
Number of CTC / lymphocytes removed
Time Frame: 1 day
Secondary Outcomes
No secondary outcomes reported
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Recruiting
Not Applicable
SentiMag Multicentre Trial.Breast CancerSentinel Lymph Node Biopsy (SLNB)Detection of Lymph Node metastases using MRINL-OMON23320This trial is jointly sponsored by King’s College London and Guy’s & St Thomas’ NHS Trust. The trial is being coordinated by the SentiMAG Trials Office, Department of Research Oncology, King’s College London.160
Completed
Not Applicable
Frequency of Circulating Tumour Cells in Stage II and Stage III Colon Cancer PatientsColon CancerNCT00351572Alberta Health services30
Completed
Not Applicable
Sentinel Node Biopsy using Magnetic Nanoparticles for melanomaCancerISRCTN15768185King's College London (UK)160
Completed
Not Applicable
Intracorporeal Nanocomposites and Neurological Disorders in Fulgurates (FulgurnanoF)Neurologic DisorderNCT04380194University Hospital, Clermont-Ferrand27
Completed
Not Applicable
Peripheral Blood and/or Bone Marrow, Including Detection of Occult Metastases, in Patients With MelanomaMelanomaNCT00588198Memorial Sloan Kettering Cancer Center754